Scientists probe how meningitis vaccines spark immunity
NCT ID NCT01593514
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how different meningococcal vaccines affect B cells, the white blood cells that produce antibodies. Researchers gave 20 healthy adults aged 30-70 either a polysaccharide or conjugate vaccine and then measured their B cell responses. The goal was to understand which vaccine type triggers a stronger and longer-lasting immune response, which could help improve future vaccines against meningitis and septicemia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Meningococcal ACWY conjugate vaccine (Menveo) and meningococcal ACWY polysaccharide vaccine (ACWYVax)
What this could lead to
If successful, this study could help researchers design better meningococcal vaccines that provide longer-lasting protection across all age groups.
What could go wrong
This is a small, early-stage knowledge-gathering study with only 20 adults, not designed to test a new treatment or vaccine. Results may not apply to children or other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MENINGITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Oxford Vaccine Group
Oxford, Oxfordshire, OX3 7LE, United Kingdom